I've drawn the analogy to Dendreon/Provenge where it's a life extending insurance unfriendly drug wheareas ours is a life improving insurance friendly product.  Dendreon ran from pennies to 57 bucks before the Greece contagion and regulatory and funding issues took it to the current level.  Frankly, to get where it is now would make many a SVFC millionaire.  So, lessons learned from the Provenge story are funding, patent protection, and revenues, not to mention timely reporting.  JMO.  GLTA!  $SVFC